FDA draft guidance paves way for more real-world, point-of-care clinical trials
Regulatory NewsEmily Hayes
Biologics/ biosimilars/ vaccinesClinical TrialsGuidancePharmaceuticalsRWE/RWDUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsEmily HayesBiologics/ biosimilars/ vaccinesClinical TrialsGuidancePharmaceuticalsRWE/RWDUnited StatesUS Food and Drug Administration (FDA)